SpyGlass Pharma, Inc.

SpyGlass is developing novel treatments for chronic ophthalmic diseases.

General Information
Company Name
SpyGlass Pharma, Inc.
Founded Year
2019
Location (Offices)
Aliso Viejo, United States +1
Founders / Decision Makers
Glenn Sussman - Co-Founder and CTO Patrick Mooney - CEO
Number of Employees
40
Industries
Pharmaceutical, Logistics and Delivery
Funding Stage
Series C
Social Media

SpyGlass Pharma, Inc. - Company Profile

SpyGlass Pharma, Inc. is a pharmaceutical startup that is focused on developing novel treatments for chronic ophthalmic diseases. Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman, the company is based in the United States and was established in 2019. Their technology, which originates from the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine, forms the foundation for their innovation in treating ophthalmic conditions. In its latest funding round on 10 July 2023, SpyGlass Pharma, Inc. secured a significant $90.00M Series C investment from a group of prominent investors including New Enterprise Associates, RA Capital Management, Samsara BioCapital, Vensana Capital, and Vertex Ventures HC. The company’s mission to develop pioneering treatments aligns with the increasing demand for innovative solutions in the pharmaceutical industry. With the support of experienced investors, SpyGlass Pharma, Inc. stands poised to make a meaningful impact in the field of ophthalmic medicine and potentially offer groundbreaking solutions for patients with chronic eye diseases.

Taxonomy: ophthalmic diseases, treatments, chronic diseases, pharmaceuticals, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Dr. Malik Y. Kahook, Glenn Sussman, startup, innovation, medical innovation

Funding Rounds & Investors of SpyGlass Pharma, Inc. (3)

View All
Funding Stage Amount No. Investors Investors Date
Series C $90.00M 5
New Enterprise Associates, investor in SpyGlass Pharma, Inc.'s Series C round RA Capital Management, investor in SpyGlass Pharma, Inc.'s Series C round Samsara BioCapital, investor in SpyGlass Pharma, Inc.'s Series C round Vensana Capital, investor in SpyGlass Pharma, Inc.'s Series C round Vertex Ventures HC, investor in SpyGlass Pharma, Inc.'s Series C round
10 Jul 2023
Venture Round $13.75M - 04 Jan 2021
Venture Round $6.03M - 05 Jun 2019

Latest News of SpyGlass Pharma, Inc.

View All

No recent news or press coverage available for SpyGlass Pharma, Inc..

Similar Companies to SpyGlass Pharma, Inc.

View All
Antlia Bioscience, Inc. - Similar company to SpyGlass Pharma, Inc.
Antlia Bioscience, Inc. Turning promising peptides into groundbreaking therapeutics for chronic diseases
Intercept Pharmaceuticals - Similar company to SpyGlass Pharma, Inc.
Intercept Pharmaceuticals Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.
Gene Vector - Similar company to SpyGlass Pharma, Inc.
Gene Vector Pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases.
Vico Medical - Similar company to SpyGlass Pharma, Inc.
Vico Medical Innovative medical devices advancing cardiovascular and cerebrovascular care
KeyNeurotek Pharmaceuticals - Similar company to SpyGlass Pharma, Inc.
KeyNeurotek Pharmaceuticals Pioneering the next generation of small molecule therapies for neuronal and autoimmune conditions.